Randomised controlled trial on vitreoretinal surgery with and without oral anticoagulants: surgical complications, visual results and perioperative thromboembolic events

• Published in: Current controlled trials in cardiovascular medicine 2019-12, Vol.20 (1), p.677-677, Article 677
• Main Authors: Andonegui, Jose, Capdevila, Ferran, Zubicoa, Alicia, Ibáñez, Berta
• Format: Article
• Language: English
• Subjects: Anesthesia; Anticoagulants; Apixaban; Care and treatment; Clinical medicine; Clinical trials; Comparative analysis; Complications; Consent; Edoxaban; Eye surgery; Ophthalmology; Pars plana vitrectomy; Patients; Physicians; Retirement benefits; Rivaroxaban; Schedules; Study Protocol; Surgical outcomes; Thromboembolism
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-019-3805-6

Vitreoretinal surgery in anticoagulated patients is a challenging situation for vitreoretinal surgeons, who have to choose between being faced with the systemic thromboembolic risks that the interruption of anticoagulation involves, or the intra- and postoperative haemorrhagic risks associated with maintenance of this therapy. So far, no trial has compared, in a prospective and randomized manner, perioperative complications and the visual results associated with continuation or interruption of oral anticoagulant therapy before pars plana vitrectomy (PPV) under retrobulbar anaesthesia. The main objective of this trial is to compare haemostasis-related perioperative complications of PPV in patients maintaining anticoagulant therapy before surgery compared to patients with an interruption in this therapy before surgery. Ninety-six patients will be randomly assigned to either the control group, in whom oral anticoagulant therapy will be interrupted and substituted with subcutaneous heparin according to local clinical practice, or the intervention group in whom oral anticoagulant therapy will not be interrupted before surgery. Patients will be stratified according to the oral anticoagulant they were taking (direct or indirect anticoagulation). They will be followed up for 12 weeks, and the primary outcome, and haemorrhagic complications until 15 days after surgery, will be evaluated. This trial will provide novel information on the possibility of continuing anticoagulant therapy during PPV. The benefits expected from the change in the current surgical management paradigm for anticoagulated patients would be a decreased risk in the incidence of perioperative thromboembolic events and the possibility of performing surgery without delay and without the need for patients to change their usual anticoagulation protocol to the more complex and less safe substitutive therapy. Clinical Trials Register EudraCT, 2018-000753-45. Registered on 11 November 2018.